Siddak M Kanwar1, Amit Noheria2, Christopher V DeSimone2, Alejandro A Rabinstein3, Samuel J Asirvatham4. 1. University of Wisconsin, Madison, Wisconsin. 2. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. 3. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 4. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: We analyzed the literature to assess the coincidental impact on migraines of transcatheter patent foramen ovale (PFO) closure performed for secondary stroke prevention. METHODS: We searched Medline, EMBASE, and the Cochrane database for studies published up until August 2013. We included English-language studies that provided information on complete resolution or improvement in migraine headaches following PFO closure. Two study authors identified 375 original articles and both independently reviewed 32 relevant manuscripts. Data including study methodology, inclusion criteria, PFO closure and migraine outcomes were extracted manually from all eligible studies. Pooled odds (and probability) of resolution or improvement of migraine headaches were calculated using random-effects models. RESULTS: Twenty studies were analyzed. Most were uncontrolled studies that included a small number of patients with cryptogenic stroke who had undergone PFO closure and had variable time of followup. The probability of complete resolution of migraine with PFO closure (18 studies, 917 patients) was 0.46 (95% confidence interval 0.39, 0.53) and of any improvement in migraine (17 studies, 881 patients) was 0.78 (0.74, 0.82). There was evidence for publication bias in studies reporting on improvement in migraines (Begg's p=0.002), but not for studies on complete resolution of migraine (p=0.3). In patients with aura, the probability of complete resolution of migraine post-PFO closure was 0.54 (0.43, 0.65), and in those without aura, complete resolution occurred in 0.39 (0.29, 0.51). CONCLUSIONS: Among patients with unexplained stroke and migraine undergoing transcatheter PFO closure, resolution of headaches occurred in a majority of patients with aura and for a smaller proportion of patients without aura.
BACKGROUND: We analyzed the literature to assess the coincidental impact on migraines of transcatheter patent foramen ovale (PFO) closure performed for secondary stroke prevention. METHODS: We searched Medline, EMBASE, and the Cochrane database for studies published up until August 2013. We included English-language studies that provided information on complete resolution or improvement in migraine headaches following PFO closure. Two study authors identified 375 original articles and both independently reviewed 32 relevant manuscripts. Data including study methodology, inclusion criteria, PFO closure and migraine outcomes were extracted manually from all eligible studies. Pooled odds (and probability) of resolution or improvement of migraine headaches were calculated using random-effects models. RESULTS: Twenty studies were analyzed. Most were uncontrolled studies that included a small number of patients with cryptogenic stroke who had undergone PFO closure and had variable time of followup. The probability of complete resolution of migraine with PFO closure (18 studies, 917 patients) was 0.46 (95% confidence interval 0.39, 0.53) and of any improvement in migraine (17 studies, 881 patients) was 0.78 (0.74, 0.82). There was evidence for publication bias in studies reporting on improvement in migraines (Begg's p=0.002), but not for studies on complete resolution of migraine (p=0.3). In patients with aura, the probability of complete resolution of migraine post-PFO closure was 0.54 (0.43, 0.65), and in those without aura, complete resolution occurred in 0.39 (0.29, 0.51). CONCLUSIONS: Among patients with unexplained stroke and migraine undergoing transcatheter PFO closure, resolution of headaches occurred in a majority of patients with aura and for a smaller proportion of patients without aura.
Authors: Peter Wilmshurst; Simon Nightingale; Matthew Pearson; Lindsay Morrison; Kevin Walsh Journal: Am J Cardiol Date: 2006-08-02 Impact factor: 2.778
Authors: Mark Reisman; Ryan D Christofferson; Jill Jesurum; John V Olsen; Merrill P Spencer; Kimberly A Krabill; Lance Diehl; Sheena Aurora; William A Gray Journal: J Am Coll Cardiol Date: 2005-02-15 Impact factor: 24.094
Authors: Sameer V Nagpal; Stamatios Lerakis; Peter B Flueckiger; Michael Halista; Patrick Willis; Peter C Block; John S Douglas; Douglas C Morris; David A Liff; James Stewart; Chethan Devireddy; Emir Veledar; Fadi B Nahab; Vasilis C Babaliaros Journal: Am J Med Sci Date: 2013-09 Impact factor: 2.378
Authors: Justin G L M Luermans; Martijn C Post; Frederik Temmerman; Vincent Thijs; Wouter J Schonewille; H W Thijs Plokker; Maarten J Suttorp; Werner I H L Budts Journal: Acta Cardiol Date: 2008-10 Impact factor: 1.718
Authors: Marianna Vachalcová; Monika Jankajová; Marta Jakubová; Karolina Angela Sieradzka; Tibor Porubän; Gabriel Valočik; Peter Šafár; Daniela Ondušová; Ján Petruš; Ingrid Schusterová Journal: J Clin Med Date: 2022-04-05 Impact factor: 4.241